Author:
Zhang Huiyuan,Dou Jun,Yu Yang,Zhao Yanling,Fan Yihui,Cheng Jin,Xu Xin,Liu Wei,Guan Shan,Chen Zhenghu,shi Yan,Patel Roma,Vasudevan Sanjeev A.,Zage Peter E.,Zhang Hong,Nuchtern Jed G.,Kim Eugene S.,Fu Songbin,Yang Jianhua
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Biochemistry, medical,Cell Biology,Clinical Biochemistry,Pharmaceutical Science,Pharmacology
Reference48 articles.
1. Brodeur GM (2003) Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3:203–216
2. Schwab M, Westermann F, Hero B, Berthold F (2003) Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol 4:472–480
3. Jacinto E, Hall MN (2003) Tor signalling in bugs, brain and brawn. Nat Rev Mol Cell Biol 4:117–126
4. Hsieh AC, Costa M, Zollo O, Davis C, Feldman ME, Testa JR et al (2010) Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell 17:249–261
5. Li J, Xue L, Hao H, Han Y, Yang J, Luo J (2012) Rapamycin provides a therapeutic option through inhibition of mTOR signaling in chronic myelogenous leukemia. Oncol Rep 27:461–466
Cited by
50 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献